Viridian Therapeutics Ors Inc (VRDN) financials
Viridian Therapeutics Ors revenue and earnings by year
Viridian Therapeutics Ors's revenue was $70.8 million in the fiscal year to December 31, 2025, up 23359.9% from the year before. Net income was -$343 million, -483.6% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 39.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71 | 0 | 0 | 2 | 3 | 1 | 4 | 8 | 4 | 3 |
| Revenue growth | 23359.9% | -3.8% | -82.3% | -40.2% | 182.2% | -76.5% | -46.8% | 109.5% | 15.1% | — |
| Operating income | -363 | -299 | -254 | -134 | -80 | -110 | -42 | -33 | -27 | -17 |
| Operating margin | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% | -10512.4% | -941.0% | -394.5% | -662.8% | -488.6% |
| Net income | -343 | -270 | -238 | -130 | -79 | -111 | -42 | -33 | -27 | -17 |
| Net margin | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -496.8% |
| Diluted EPS | — | — | -$5.31 | -$4.05 | -$6.66 | — | — | — | — | — |
| Free cash flow | -277 | -233 | -185 | -95 | -55 | -30 | -36 | -27 | -28 | -15 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open VRDN in Markets.
See also: VRDN returns
No forecast, no recommendation. This page describes Viridian Therapeutics Ors Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.